Eddingpharm gets rights to Immutep's ImmuFact IMP321
Specialty pharmaceuticals company Eddingpharm International Holdings Ltd. licensed exclusive rights to develop, manufacture, and sell oncology firm Immutep SA’s ImmuFact IMP321 in China, Hong Kong, Macau, and Taiwan.
- Specialty Pharmaceuticals
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.